In conclusion, SR-BI-mediated cholesterol efflux capacity is reduced in patients with diffuse coronary atherosclerosis and lower SR-BI-mediated cholesterol efflux capacity is associated with the worst clinical outcomes in patients with CAD, independently of atherosclerotic plaque features. The gene discussed is SCARB1; the disease is coronary artery disorder.